[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Streeterville Capital LLC, Streeterville Management LLC and their principal John M. Fife have become 9.9% beneficial owners of Garden Stage Ltd (GSIW). In a Schedule 13G dated 24 July 2025, the group disclosed ownership of 7,110,764 ordinary shares out of 71,178,820 shares outstanding. All voting and dispositive rights are held solely by the reporting persons; no shared power is reported.

The filing—made under Rule 13d without any stated intent to influence control—classifies the entities as “OO” (other) investors. Address information shows operations managed from Chicago, while the issuer is headquartered in Hong Kong. The certification affirms the stake was acquired for investment purposes only.

Positive

• Streeterville group reveals a 9.9% position, introducing a sizeable outside shareholder that may enhance share liquidity and institutional visibility.

Negative

• None.

Insights

Securities Analyst

TL;DR: 9.9% stake signals a new large holder; no control intent disclosed—market impact likely limited unless stake grows.

The Schedule 13G introduces Streeterville Capital and related parties as the fourth-largest shareholder, just shy of the 10% threshold that would trigger additional regulatory obligations. Because the group retains sole voting/dispositive power but expressly disclaims any control motive, the filing is largely informational. The 9.9% cap suggests the investors wish to avoid insider status, reducing immediate governance implications. While a stake of this size may boost liquidity perceptions and indicates external confidence, there is no accompanying capital infusion or strategic partnership, keeping the net effect neutral.

Corporate Governance Expert

TL;DR: Passive 13G filing adds a significant shareholder; governance risk appears low given no group or control ambitions.

From a governance standpoint, the disclosure satisfies SEC transparency rules, enabling other investors to gauge ownership concentration. The sole-power structure and passive certification lessen the likelihood of proxy influence or board challenges. However, the presence of one individual—John M. Fife—as ultimate owner of the entire block centralises influence should objectives change. Investors should monitor future filings (13D amendments or Form 4s) for any shift above the 10% mark or a move to an active stance.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2025

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F                                 Form 40-F   

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes                                       No   

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated July 24, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: July 24, 2025	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

FAQ

How many Garden Stage (GSIW) shares does Streeterville own?

The filing reports 7,110,764 ordinary shares beneficially owned.

What percentage of Garden Stage’s outstanding shares is held?

Streeterville's stake equals 9.9% of the 71,178,820 shares outstanding as of 24 July 2025.

Does the investor have control intentions over GSIW?

No. The certification states the shares were not acquired to influence control of the issuer.

Who signed the Schedule 13G for Streeterville?

John M. Fife signed as President of both Streeterville entities and in his individual capacity.

Under which SEC rule was this Schedule 13G filed?

The box selections indicate filing under the passive investment provisions of Rule 13d-1 (exact subsection not specified).